206 related articles for article (PubMed ID: 14683500)
1. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies.
Fonsatti E; Sigalotti L; Arslan P; Altomonte M; Maio M
Curr Cancer Drug Targets; 2003 Dec; 3(6):427-32. PubMed ID: 14683500
[TBL] [Abstract][Full Text] [Related]
2. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies.
Fonsatti E; Del Vecchio L; Altomonte M; Sigalotti L; Nicotra MR; Coral S; Natali PG; Maio M
J Cell Physiol; 2001 Jul; 188(1):1-7. PubMed ID: 11382917
[TBL] [Abstract][Full Text] [Related]
3. Endoglin (CD105): a target for anti-angiogenetic cancer therapy.
Fonsatti E; Altomonte M; Arslan P; Maio M
Curr Drug Targets; 2003 May; 4(4):291-6. PubMed ID: 12699349
[TBL] [Abstract][Full Text] [Related]
4. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.
Fonsatti E; Altomonte M; Nicotra MR; Natali PG; Maio M
Oncogene; 2003 Sep; 22(42):6557-63. PubMed ID: 14528280
[TBL] [Abstract][Full Text] [Related]
5. Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(5A):3621-8. PubMed ID: 9858949
[TBL] [Abstract][Full Text] [Related]
6. Differential expression and cytoplasm/membrane distribution of endoglin (CD105) in human tumour cell lines: Implications in the modulation of cell proliferation.
Postiglione L; Di Domenico G; Caraglia M; Marra M; Giuberti G; Del Vecchio L; Montagnani S; Macri M; Bruno EM; Abbruzzese A; Rossi G
Int J Oncol; 2005 May; 26(5):1193-201. PubMed ID: 15809709
[TBL] [Abstract][Full Text] [Related]
7. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma.
Behrem S; Zarkovic K; Eskinja N; Jonjic N
Croat Med J; 2005 Jun; 46(3):417-22. PubMed ID: 15861521
[TBL] [Abstract][Full Text] [Related]
8. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas.
Salvesen HB; Gulluoglu MG; Stefansson I; Akslen LA
APMIS; 2003 Nov; 111(11):1011-8. PubMed ID: 14629267
[TBL] [Abstract][Full Text] [Related]
9. CD105 is important for angiogenesis: evidence and potential applications.
Duff SE; Li C; Garland JM; Kumar S
FASEB J; 2003 Jun; 17(9):984-92. PubMed ID: 12773481
[TBL] [Abstract][Full Text] [Related]
10. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy.
Nassiri F; Cusimano MD; Scheithauer BW; Rotondo F; Fazio A; Yousef GM; Syro LV; Kovacs K; Lloyd RV
Anticancer Res; 2011 Jun; 31(6):2283-90. PubMed ID: 21737653
[TBL] [Abstract][Full Text] [Related]
11. Endoglin (CD105) expression in squamous cell carcinoma of the oral cavity.
Schimming R; Marmé D
Head Neck; 2002 Feb; 24(2):151-6. PubMed ID: 11891945
[TBL] [Abstract][Full Text] [Related]
12. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours.
Fonsatti E; Nicolay HJ; Altomonte M; Covre A; Maio M
Cardiovasc Res; 2010 Apr; 86(1):12-9. PubMed ID: 19812043
[TBL] [Abstract][Full Text] [Related]
13. Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers.
Minhajat R; Mori D; Yamasaki F; Sugita Y; Satoh T; Tokunaga O
Virchows Arch; 2006 Feb; 448(2):127-34. PubMed ID: 16177881
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105.
Li C; Guo B; Bernabeu C; Kumar S
Microsc Res Tech; 2001 Feb; 52(4):437-49. PubMed ID: 11170303
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
16. Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers.
Minhajat R; Mori D; Yamasaki F; Sugita Y; Satoh T; Tokunaga O
Pathol Int; 2006 Dec; 56(12):717-23. PubMed ID: 17096728
[TBL] [Abstract][Full Text] [Related]
17. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer.
Wikström P; Lissbrant IF; Stattin P; Egevad L; Bergh A
Prostate; 2002 Jun; 51(4):268-75. PubMed ID: 11987155
[TBL] [Abstract][Full Text] [Related]
18. Analysis of neovasculature in uveal melanoma by targeting the TGFbeta-binding receptor endoglin: is there prognostic relevance of proliferating endothelium?
Ziemssen F; Wegner R; Wegner J; Tatar O; Süsskind D; Gelisken F; Rohrbach M; Bartz-Schmidt KU; Grisanti S
Graefes Arch Clin Exp Ophthalmol; 2006 Sep; 244(9):1124-31. PubMed ID: 16523306
[TBL] [Abstract][Full Text] [Related]
19. [Endoglin (CD105)--a target for visualization and anti-angiogenic therapy for malignant tumors].
Smirnov IV; Gryazeva IV; Samoilovich MP; Klimovich VB
Vopr Onkol; 2015; 61(6):898-907. PubMed ID: 26995976
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(3A):1485-500. PubMed ID: 9673360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]